Zacks Small Cap Estimates Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Cytosorbents in a research note issued on Friday, April 4th. Zacks Small Cap analyst T. Kerr anticipates that the medical research company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents' Q2 2025 earnings at ($0.06) EPS.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Other equities analysts have also recently issued research reports about the stock. StockNews.com started coverage on shares of Cytosorbents in a research note on Friday. They issued a "hold" rating for the company. HC Wainwright reiterated a "neutral" rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Thursday, April 3rd. Finally, D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a research report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $4.67.

Remove Ads

Cytosorbents Price Performance

Shares of CTSO stock traded up $0.03 during trading on Monday, hitting $0.97. The company had a trading volume of 110,425 shares, compared to its average volume of 144,179. The stock's 50-day moving average is $1.06 and its two-hundred day moving average is $1.02. The stock has a market capitalization of $60.75 million, a price-to-earnings ratio of -2.70 and a beta of 1.17. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares during the period. Skylands Capital LLC grew its stake in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock valued at $2,531,000 after buying an additional 26,195 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents in the fourth quarter worth about $99,000. Renaissance Technologies LLC lifted its stake in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Avenir Corp boosted its holdings in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.